title: Outcome of Kaposi's sarcoma and graft following discontinuation of immunosuppressive drugs in renal transplant recipients.
abstract: OBJECTIVE
  Owing to the use of immunosuppressive drugs, renal transplant recipients are at risk for malignancies including Kaposi's sarcoma (KS). Following the diagnosis, physicians tend to decrease the doses of immunosuppressive drugs to lower tumor progression rate. On the other hand, those who receive lower doses of immunosuppressive drugs are at a higher risk for acute rejection. In this study, we evaluated the outcome of KS on renal allografts following discontinuation or decrease in the doses of drugs.
  
  
  METHODS
  Since 1984, 14 (nine men and five women) among 2000 cases of renal transplantation have been diagnosed as KS. In 11 patients, cyclosporine was completely discontinued, the dosage was decreased to half of the initial dose in other cases. Except one case, we discontinued either azathioprine or mycophenolate mofetil.
  
  
  RESULTS
  During 57 months of follow-up on average, the serum creatinine level remained normal in 10 but increased in four cases. Kidney function deteriorated in two of these four patients at the beginning of study. Three patients died with normal serum creatinine levels. Discontinuation of immunosuppressive drugs caused complete remission of KS in all patients except one who received chemotherapy.
  
  
  CONCLUSIONS
  Discontinuation of immunosuppressants following the diagnosis of KS caused complete remission of this cancer in almost all patients and seemed to be relatively safe for kidney graft function.
authors.affiliation: Urology Nephrology Research Center, Islamic Azad University-Tehran Medical Unit, Tehran, Iran. h_sasan@hotmail.com
authors.forename: A
authors.initials: A
authors.lastname: Firoozan
authors.forename: S M M
authors.initials: SM
authors.lastname: Hosseini Moghaddam
authors.forename: B
authors.initials: B
authors.lastname: Einollahi
authors.forename: F
authors.initials: F
authors.lastname: Pour-Reza-Gholi
authors.forename: M
authors.initials: M
authors.lastname: Nafar
authors.forename: A
authors.initials: A
authors.lastname: Basiri
authors.forename: R
authors.initials: R
authors.lastname: Ebrahimi-Rad
mesh_terms: D000328:Adult; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D015994:Incidence; D016030:Kidney Transplantation / Q000009:adverse effects / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000821:virology*; D012189:Retrospective Studies; D012514:Sarcoma, Kaposi / Q000175:diagnosis / Q000453:epidemiology*
chemical_list: D007166:Immunosuppressive Agents